ADAR1 Capital Management, LLC 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
ADAR1 Capital Management, LLC disclosed 199 US equity positions worth $485.2m in its Q4 2024 13F filing. The largest position was ROIV at 8.6% of the reported book, followed by PTGX and BOXX. Against the Q3 2024 filing, it opened 10 new positions, added to 23 and reduced 15 among the top 50 holdings.
What did ADAR1 Capital Management, LLC own in Q4 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | ROIV ROIVANT SCIENCES LTD | Healthcare | 8.6% | $41.5m | 3,508,694 | 16% | added |
| 2 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 8.1% | $39.4m | 1,020,333 | 4% | added |
| 3 | BOXX EA SERIES TRUST | 7.4% | $35.9m | 325,450 | 1% | added | |
| 4 | ZLAB ZAI LAB LTD | Healthcare | 5.6% | $27.4m | 1,045,837 | 96% | added |
| 5 | IMVT IMMUNOVANT INC | Healthcare | 4.0% | $19.5m | 787,478 | -30% | reduced |
| 6 | CYTK CYTOKINETICS INC | Healthcare | 4.0% | $19.5m | 414,209 | -55% | reduced |
| 7 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 3.8% | $18.6m | 678,857 | -53% | reduced |
| 8 | IKT INHIBIKASE THERAPEUTICS INC | 3.4% | $16.6m | 5,103,005 | – | new | |
| 9 | BIL SPDR SER TR | 2.5% | $12.0m | 131,786 | 505% | added | |
| 10 | ABVX ABIVAX SA | 2.3% | $11.1m | 1,513,393 | 190% | added | |
| 11 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 2.1% | $10.4m | 841,541 | 15% | added |
| 12 | ASND ASCENDIS PHARMA A/S | Healthcare | 2.0% | $9.8m | 71,402 | -56% | reduced |
| 13 | PERCEPTIVE CAP SOLUTIONS COR | 1.6% | $7.6m | 750,000 | 0% | held | |
| 14 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.5% | $7.4m | 170,000 | 283% | added |
| 15 | RZLT REZOLUTE INC | 1.4% | $6.7m | 1,359,208 | -14% | reduced | |
| 16 | 0C3 ENDEAVOR GROUP HLDGS INC | 1.4% | $6.6m | 210,729 | 72% | added | |
| 17 | CGON CG ONCOLOGY INC | Healthcare | 1.3% | $6.2m | 215,750 | 51% | added |
| 18 | AVR ANTERIS TECHNOLOGIES GLOBAL | 1.2% | $5.9m | 1,052,968 | – | new | |
| 19 | AA MISSION ACQUISITION CORP | 1.2% | $5.7m | 560,199 | -45% | reduced | |
| 20 | COHERUS BIOSCIENCES INC | 1.1% | $5.5m | 5,625,000 | – | new | |
| 21 | XNCR XENCOR INC | Healthcare | 1.1% | $5.4m | 234,607 | -31% | reduced |
| 22 | ZURA ZURA BIO LTD | Healthcare | 1.1% | $5.2m | 2,077,251 | -45% | reduced |
| 23 | ABUS ARBUTUS BIOPHARMA CORP | Healthcare | 1.0% | $5.1m | 1,554,802 | -26% | reduced |
| 24 | OAKTREE ACQUISITION CORP III | 1.0% | $5.1m | 500,000 | – | new | |
| 25 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 1.0% | $4.9m | 40,002 | 463% | added |
| 26 | SNY SANOFI | 1.0% | $4.8m | 99,600 | – | new | |
| 27 | GOSSAMER BIO INC | 0.9% | $4.4m | 8,000,000 | – | new | |
| 28 | HELIX ACQUISITION CORP II | 0.9% | $4.2m | 404,138 | 0% | held | |
| 29 | ETNBGBP 89BIO INC | 0.8% | $4.0m | 515,138 | 7753% | added | |
| 30 | BBIO BRIDGEBIO PHARMA INC | 0.8% | $3.9m | 4,500,000 | – | new | |
| 31 | MERUS N V | 0.7% | $3.4m | 81,460 | -47% | reduced | |
| 32 | KINIKSA PHARMACEUTICALS INTL | 0.7% | $3.3m | 166,406 | -62% | reduced | |
| 33 | ALDX ALDEYRA THERAPEUTICS INC | Healthcare | 0.7% | $3.2m | 647,960 | 114% | added |
| 34 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 0.7% | $3.2m | 146,671 | 36% | added |
| 35 | SVRA SAVARA INC | Healthcare | 0.6% | $3.0m | 988,468 | 33% | added |
| 36 | GRCE GRACE THERAPEUTICS INC | 0.6% | $2.9m | 773,635 | -19% | reduced | |
| 37 | MNPR MONOPAR THERAPEUTICS INC | 0.6% | $2.9m | 130,037 | – | new | |
| 38 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 0.6% | $2.7m | 53,125 | -40% | reduced | |
| 39 | TECX TECTONIC THERAPEUTIC INC | Healthcare | 0.6% | $2.7m | 58,708 | -54% | reduced |
| 40 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 0.5% | $2.7m | 211,400 | 4816% | added |
| 41 | CNTA CENTESSA PHARMACEUTICALS PLC | 0.5% | $2.6m | 154,027 | 561% | added | |
| 42 | AEROVATE THERAPEUTICS INC | 0.5% | $2.5m | 928,016 | 721% | added | |
| 43 | KRRO KORRO BIO INC | Healthcare | 0.5% | $2.2m | 57,978 | 17% | added |
| 44 | PTCT PTC THERAPEUTICS INC | Healthcare | 0.4% | $2.2m | 48,023 | 140% | added |
| 45 | A SPAC III ACQUISITION CORP | 0.4% | $2.2m | 215,000 | – | new | |
| 46 | BBIO BRIDGEBIO PHARMA INC | 0.4% | $2.1m | 2,000,000 | – | new | |
| 47 | XENE XENON PHARMACEUTICALS INC | Healthcare | 0.4% | $2.0m | 50,547 | 81% | added |
| 48 | APGE APOGEE THERAPEUTICS INC | Healthcare | 0.4% | $1.9m | 41,274 | -28% | reduced |
| 49 | RAPT THERAPEUTICS INC | 0.4% | $1.9m | 1,174,313 | 15558% | added | |
| 50 | DCTH DELCATH SYS INC | 0.4% | $1.8m | 149,385 | 381% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.